脑胶质瘤是起源于脑胶质细胞的预后极差的恶性肿瘤，基因治疗药物凭借其精准的靶向性和免疫调节机制在脑胶质瘤治疗上展现了一些新突破。基因治疗按产品形式可分为体外基因治疗和体内基因治疗，体外基因治疗主要涉及基因改造的细胞治疗产品，肿瘤治疗药物中较成功的是嵌合抗原受体T细胞免疫疗法，而体内基因治疗主要包括以病毒载体为主的基因治疗，在肿瘤治疗中进展比较快的是溶瘤病毒。总结了细胞治疗产品和基因治疗产品治疗脑胶质瘤的研究进展，为临床应用提供参考。

Gliomas are malignant tumors originating from glial cells with extremely poor prognosis. Gene therapy products have shown some new breakthroughs in the treatment of gliomas due to their precise targeting and immune regulatory mechanisms. Gene therapy can be mainly divided into in vitro gene therapy and in vivo gene therapy. In vitro gene therapy mainly involves genetically modified cell therapy products, while CAR-T is the most successful in tumor therapy. In vivo gene therapy mainly includes gene therapy based on viral vectors, with oncolytic virus being the most attractive tumor therapy. This article summarizes the research progress in cell therapy products and gene therapy products for treating gliomas, providing a reference for clinical applications.

R979.1

山东省重点研发计划（企业创新能力提升工程）项目（2026QYTSGC02018）；天津市教委科研计划项目（2023KJ106）